title: Effect of anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats.
abstract: Disruption of normal neuronal networks and neurotransmitters like serotonin and norepinephrine levels in post traumatic brain injury (TBI) are observed to be the primary causative agent for depression/anxiety. This communication reports the efficacy of various classes' anti-depressants in the treatment of depression/anxiety following TBI in rats. Chronic treatment with anti-depressants (escitalopram and venlafaxine) leads to improvement in the depressive/anxiogenic-like behaviour in the TBI rat and corroborates the notion of the involvement of serotonin and norepinephrine in the behavioural consequences of post-TBI. Chronic treatments with escitalopram and venlafaxine significantly reversed the effect of TBI as compared to vehicle-treated TBI group. The results showed a quantitative battery of neuro-behavioural functional assessments that correlates with neuronal damage following traumatic brain injury.
authors.affiliation: Department of Pharmacy, FD-III, Birla Institute of Technology & Science, Pilani 333 031, India.
authors.forename: Radhakrishnan
authors.initials: R
authors.lastname: Mahesh
authors.forename: Dilip Kumar
authors.initials: DK
authors.lastname: Pandey
authors.forename: Shruti
authors.initials: S
authors.lastname: Katiyar
authors.forename: Gaurav
authors.initials: G
authors.lastname: Kukade
authors.forename: Shruti
authors.initials: S
authors.lastname: Viyogi
authors.forename: Anjuman
authors.initials: A
authors.lastname: Rudra
mesh_terms: D000054:Acceleration / Q000009:adverse effects*; D000639:Amitriptyline / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy / Q000209:etiology; D001522:Behavior, Animal / Q000187:drug effects*; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D016642:Bupropion / Q000494:pharmacology / Q000627:therapeutic use; D015283:Citalopram / Q000494:pharmacology / Q000627:therapeutic use; D003511:Cyclohexanols / Q000494:pharmacology / Q000627:therapeutic use; D005106:Exploratory Behavior / Q000187:drug effects; D005239:Fear / Q000187:drug effects; D008297:Male; D009473:Neuronal Plasticity; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D009638:Norepinephrine / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D013216:Reflex, Startle / Q000187:drug effects; D012701:Serotonin / Q000502:physiology*; D012919:Social Behavior; D000069470:Venlafaxine Hydrochloride
chemical_list: D000928:Antidepressive Agents; D003511:Cyclohexanols; D014179:Neurotransmitter Uptake Inhibitors; D016642:Bupropion; D015283:Citalopram; D000639:Amitriptyline; D012701:Serotonin; D000069470:Venlafaxine Hydrochloride; D009638:Norepinephrine